Abstract
Objective:Irisin, mostly known as an exercise-induced fat browning myokine, has been recently detected in several cancer cells, and its potential for being utilized as a biomarker for early diagnosis of some cancers, such as Gastric cancer (GC), is the subject of speculation. The present study aims to compare serum irisin levels in GC patients and healthy controls and assess the interrelation between irisin and oxidative stress markers. Methods:In this case-control study, 22 newly diagnosed GC patients and 29 healthy controls were recruited based on the inclusion criteria. Serum levels of irisin were quantified in duplicates by ELISA. Oxidative stress indices, including total antioxidant power in sera, thiol group, malondialdehyde, and superoxide dismutase concentrations, were also measured in both groups. An independent-sample t-test was used to compare the means between the two studied groups. Results:Serum levels of irisin were significantly higher in the GC group compared with those of their healthy counterparts (p =0.032). No significant differences were observed between the two groups in terms of the serum total antioxidant power or the oxidative stress marker, including MDA, thiol groups, and SOD concentration in sera. Furthermore, there was no significant association between irisin, FRAP, the Thiol group, and the SOD activity. Conclusion:According to the finding, the increased serum levels of irisin in GC patients can play a potential role in the early diagnosis of the GC patients; hence, this peptide can be employed as a new diagnostic indicator of GC.
Highlights
Gastric cancer (GC), with a mortality rate of over 75%, is one of the two leading causes of cancer deaths and the fifth most common malignancy in the world (Sitarz et al, 2018)
The present study aims to compare serum irisin levels in GC patients and healthy controls and assess the interrelation between irisin and oxidative stress markers
According to the results of the present study, the serum irisin level was significantly higher in GC patients
Summary
Gastric cancer (GC), with a mortality rate of over 75%, is one of the two leading causes of cancer deaths and the fifth most common malignancy in the world (Sitarz et al, 2018). Irisin has been detected in many cancer cells, including those of breast, ovarian, lung, kidney, thyroid, and gastric; some studies have suggested a diagnostic or even therapeutic role for this protein (Askari et al, 2018). Increasing Glutathione peroxidase (GPX), catalase, and SOD activity and reducing malondialdehyde (MDA) levels are some of these proposed mechanisms (Askari et al, 2018). Considering all these issues and the want of studies, especially on humans, studying irisin levels and redox status in GC patients and comparing them with those of the normal subjects, together with investigating the interaction between irisin and oxidative status or antioxidant enzymes, seems to be a requirement, guiding us to find new diagnostic biomarkers. This study aims to investigate the irisin serum levels and redox status of GC patients and their possible interrelationship with one another
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
